Parexel VP Highlights Ongoing U.S. and European GMP Differences for Pharmaceutical Manufacturers.

Manufacturers navigating the global pharmaceutical landscape must recognize the existing distinctions between U.S. and European Good Manufacturing Practice (GMP) requirements, according to Siegfried Schmitt, PhD, Vice President, Technical at Parexel. Despite efforts toward global harmonization, manufacturers still need to be aware of differences in GMPs between the U.S. and Europe. Schmitt explains that while a global standard is the ultimate goal, companies must understand that differences between the U.S. and European GMP requirements remain. These distinctions are crucial for manufacturers aiming to comply with regulations in both regions.

Newsflash | Powered by GeneOnline AI
Date: May 2, 2025

Related posts:

Study Identifies Bacterial Invasion as a Risk Factor for Brain Implant Longevity FDA Leadership Change Raises Concerns Among Biopharma Industry Over Future Collaboration RPh Jonas Congelli Highlights How Limited Distribution Networks and Medically Integrated Pharmacies Can Improve Oncology Care Access in Underserved Communities Health Care Inc. Reports FTC Scrutiny of Hospital Mergers Amidst Inflation Reduction Act Debate on Drug Pricing.

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後